2 terminated. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
Follow TTI-621: new trials by email Literature Review of TTI-621 trials Research Report on TTI-621
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides TTI-621 Monotherapy, TTI-621 + PD-1/PD-L1 Inhibitor, TTI-621 + pegylated interferon-α2a - Solid Tumors, Mycosis Fungoides | Phase 1 | Terminated | Pfizer | 56 | 2016-09-01 | 2023-04-05 |
| A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab - Hematologic Malignancies, Solid Tumor | Phase 1 | Terminated | Pfizer | 249 | 2016-01-28 | 2024-05-10 |
Breast Neoplasms (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Squamous Cell (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1) · Melanoma (1) · Multiple Myeloma (1) · Mycosis Fungoides (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1)
Pfizer (2)
United States (2) · Canada (1)
PMID 30962222, PMID 33451977, PMID 34519839, PMID 34627593, PMID 36841672